Verona Pharma Plc ADR (VRNA)

$106.91 +0.12 (0.11%)
Market Cap 8.75B
Revenue (ttm) 42.28M
Net Income (ttm) -173.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 872.73
Profit Margin -410.17%
Debt to Equity Ratio 0.87
Volume 1,871,900
Avg Vol 1,571,794
Day's Range N/A - N/A
Shares Out 81.83M
Stochastic %K 97%
Beta 0.05
Analysts Sell
Price Target $106.00

Company Profile

Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was formerly known as Isis...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 3283 4200
Address:
3 More London Riverside, London, United Kingdom
LongLongStock
LongLongStock Jul. 2 at 1:29 AM
$VRNA my old family. $CAPR might have the same run as vrna by the end of the month, and end of next month!
3 · Reply
Jack_Danielss
Jack_Danielss Jun. 30 at 3:38 PM
$CYTK $VRNA vibes
0 · Reply
Kingjake26
Kingjake26 Jun. 30 at 2:21 PM
$CADL Totally agree. I believe $CADL is better than my $VRNA that was bought out at over $100 a share. Thats no pumping. That is just an opinion. Just do the homework
1 · Reply
Hawksssss
Hawksssss Jun. 20 at 5:20 AM
$VRNA revenue prior to and after buyout. Interesting dip in q1, not unlike many bios but quite sizable. Verona Ohtuvayre (ensifentrine) Revenue 3Q24: 5.6 mil; 4Q24: 35.65 mil; 1Q25: 76.3 mil 2Q25: 103.1 mil 3Q25: 136 mil 4Q25: 196 mil; 1Q26: 131 mil 2024: 41.2 mil 2025: 506 mil
1 · Reply
Hawksssss
Hawksssss Jun. 20 at 2:13 AM
$VRNA Apogee to be bought for 11 billion. Brief Clinical Outcome Comparison between Connect China phase 3 data and Apogee Efficacy (Week 16) 1. EASI-75: Rademikibart higher (74.2%) vs Zumilokibart (65.9%) 2. IGA 0/1 clearance: Nearly equal (Rademikibart 47.7% / Zumilokibart 46.0%) 3. EASI-90 deep clearance: Zumilokibart slightly better (47.4%) vs Rademikibart (43.0%) 4. Itch reduction: Rademikibart superior (54.7%) vs Zumilokibart (50.5%) Long-term 52-week maintenance • Rademikibart: Very high sustained response (EASI-75 96.6%, IGA 0/1 87.1%) with Q2W/Q4W dosing • Zumilokibart: 85% Week 16 responders kept EASI-75 with semi-annual ultra-long dosing Safety • Rademikibart: Lower conjunctivitis rate (3.9%) and mild overall adverse event rate • Zumilokibart: Higher conjunctivitis risk (10.6%–20.7% across doses); comparable general adverse event profile otherwise Onset speed • Rademikibart: Noticeable relief at Week 1 • Zumilokibart: Itch relief within 48 hours
0 · Reply
Hawksssss
Hawksssss Jun. 17 at 6:17 AM
$VRNA $XBI 3) The company said in March that the two acute readouts will be around mid year and will commence phase three for both acute and chronic athema. Remember Dupixent did 17.8 billion in sales. Company just raised 20 mil (it had 45 mil in cash) and insiders bought several million shares at 3.2 in the first half. It is now sitting at 2 or 125 million MC. The most important thing about this name is the fact that its China trial result was fantastic and US readouts are around the corner. So we are not really blind now. Eli Lilly and Perceptive have stake in the company. Do your own DD. Good luck!
0 · Reply
Hawksssss
Hawksssss Jun. 17 at 6:11 AM
$VRNA $VRNA $XBI if you are still around Verona. Came across this name $CNTB. It is also in the respiratory space. It has two phase 2 readouts within the next month for acute athema and COPD. There are not approved treatment for acute (emergency setting) athema or COPD. Verona’s drug is for chronic COPD, not acute. The company’s Chinese partner has finished phase 3 trial and filed a new drug application for eczema. 1)
0 · Reply
Hawksssss
Hawksssss Jun. 17 at 6:10 AM
$VRNA $CNTB 2) The Phase 3 trials in China have been a huge success. Rademikibart did not only meet its goals; it generated numbers that suggested that it could be better than the current market leader, Dupixent. In dermatology trials, eczema improvements are measured by the EASI score. By week 52, 96.6% of patients on rademikibart achieved EASI-75, which is huge compared to Dupixent, where only 65% of patients achieved EASI-75 at 52 weeks. EASI-90 was achieved by 85.3% of patients who achieved a 90% reduction in their eczema, an exceptionally high bar for a chronic autoimmune disease. For comparison, Dupixent achieved a score of 51% at 52 weeks.
0 · Reply
BioRich
BioRich Jun. 16 at 9:11 PM
$CRMD Quick look over at the gainers for today and I saw this grouping. How many Buyouts or deals did we have in this group? Good lord. Will $CRMD be added to that distinguished list? I think so. For fun, the 2 picks above the screen grab was $AKRO, one below was $NUVL. $TERN? $VRNA? Some real life changes in here. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
1 · Reply
BioRich
BioRich Jun. 15 at 3:37 PM
$MRK You bought $VRNA (thank you very much) so why not just work with Mr. Z to get a deal done for $SABS? That would be great appeciated as well. Cheers!
0 · Reply
Latest News on VRNA
Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales

Oct 6, 2025, 4:05 PM EDT - 9 months ago

Acquisition of Verona by MSD Approved by the High Court of Justice of England and Wales

Shareholders of Verona Pharma Approve Proposed Acquisition by Merck

Sep 24, 2025, 4:05 PM EDT - 10 months ago

Shareholders of Verona Pharma Approve Proposed Acquisition by Merck

Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025

Sep 16, 2025, 6:00 AM EDT - 10 months ago

Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025

VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA

Jul 12, 2025, 9:09 PM EDT - 1 year ago

VERONA PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verona Pharma plc - VRNA

MRK

Major deals involving U.S. drugmakers and biotechs over the past decade

Jul 9, 2025, 1:46 PM EDT - 1 year ago

Major deals involving U.S. drugmakers and biotechs over the past decade

MRK

Merck to Buy Verona Pharma for Around $10 Billion

Jul 9, 2025, 12:36 PM EDT - 1 year ago

Merck to Buy Verona Pharma for Around $10 Billion

MRK

Two big reasons why buying Verona was crucial for Merck

Jul 9, 2025, 10:38 AM EDT - 1 year ago

Two big reasons why buying Verona was crucial for Merck

Merck has struck a roughly $10 billion deal to buy Verona Pharma

Jul 9, 2025, 10:36 AM EDT - 1 year ago

Merck has struck a roughly $10 billion deal to buy Verona Pharma

MRK

Verona Pharma shares jump with Merck set to acquire company in $10 billion deal

Jul 9, 2025, 8:13 AM EDT - 1 year ago

Verona Pharma shares jump with Merck set to acquire company in $10 billion deal

Merck dives into COPD treatments with $10 billion purchase of Verona Pharma

Jul 9, 2025, 7:48 AM EDT - 1 year ago

Merck dives into COPD treatments with $10 billion purchase of Verona Pharma

MRK

Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.

Jul 9, 2025, 7:14 AM EDT - 1 year ago

Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.

MRK

Merck to Buy Verona Pharma in $10 Billion Deal

Jul 9, 2025, 6:48 AM EDT - 1 year ago

Merck to Buy Verona Pharma in $10 Billion Deal

MRK

Merck to acquire Verona Pharma for $10 billion

Jul 9, 2025, 6:39 AM EDT - 1 year ago

Merck to acquire Verona Pharma for $10 billion

MRK

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

Jul 9, 2025, 6:30 AM EDT - 1 year ago

Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade

MRK

Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports

Jul 9, 2025, 1:09 AM EDT - 1 year ago

Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports

MRK

Mizuho's Jared Holz details potential biotech, pharma acquisitions

Jun 4, 2025, 6:10 PM EDT - 1 year ago

Mizuho's Jared Holz details potential biotech, pharma acquisitions

INSM LEGN

Verona Pharma Announces June 2025 Investor Conference Participation

May 21, 2025, 6:00 AM EDT - 1 year ago

Verona Pharma Announces June 2025 Investor Conference Participation

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

May 6, 2025, 6:00 AM EDT - 1 year ago

Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 29, 2025, 6:00 AM EDT - 1 year ago

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS

Mar 28, 2025, 7:00 AM EDT - 1 year ago

Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 6:00 AM EST - 1 year ago

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Verona Pharma Announces March 2025 Investor Conference Participation

Feb 18, 2025, 6:00 AM EST - 1 year ago

Verona Pharma Announces March 2025 Investor Conference Participation

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

Feb 13, 2025, 6:00 AM EST - 1 year ago

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

Jan 7, 2025, 6:00 AM EST - 1 year ago

Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

Verona Pharma Announces December 2024 Investor Conference Participation

Nov 19, 2024, 2:00 AM EST - 1 year ago

Verona Pharma Announces December 2024 Investor Conference Participation

Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value

Nov 9, 2024, 8:23 AM EST - 1 year ago

Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value

Verona Pharma to Present at Jefferies London Healthcare Conference

Nov 5, 2024, 2:00 AM EST - 1 year ago

Verona Pharma to Present at Jefferies London Healthcare Conference

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 4, 2024, 2:00 AM EST - 1 year ago

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Oct 21, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

Oct 8, 2024, 5:00 AM EDT - 1 year ago

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

OCS ONCO GRDX

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024

Sep 30, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

Sep 5, 2024, 2:00 AM EDT - 1 year ago

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 8, 2024, 2:00 AM EDT - 2 years ago

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

Jul 30, 2024, 2:00 AM EDT - 2 years ago

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Jul 25, 2024, 2:00 AM EDT - 2 years ago

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month

Jun 27, 2024, 9:03 AM EDT - 2 years ago

Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month

US FDA approves Verona Pharma's therapy for 'smoker's lungs'

Jun 26, 2024, 5:13 PM EDT - 2 years ago

US FDA approves Verona Pharma's therapy for 'smoker's lungs'

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

Jun 26, 2024, 4:57 PM EDT - 2 years ago

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:15 AM EDT - 2 years ago

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS

May 9, 2024, 7:00 AM EDT - 2 years ago

Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

May 2, 2024, 2:00 AM EDT - 2 years ago

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update

Apr 25, 2024, 2:00 AM EDT - 2 years ago

Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update

Andrew Fisher Joins Verona Pharma as General Counsel

Mar 4, 2024, 2:00 AM EST - 2 years ago

Andrew Fisher Joins Verona Pharma as General Counsel

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 2:00 AM EST - 2 years ago

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

Feb 15, 2024, 2:00 AM EST - 2 years ago

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

Michael Austwick Joins Verona Pharma as Non-Executive Director

Feb 1, 2024, 2:00 AM EST - 2 years ago

Michael Austwick Joins Verona Pharma as Non-Executive Director

Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 2:00 AM EST - 2 years ago

Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference

Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital

Jan 2, 2024, 2:00 AM EST - 2 years ago

Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital

Verona Pharma's President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award

Nov 17, 2023, 2:00 AM EST - 2 years ago

Verona Pharma's President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award

LongLongStock
LongLongStock Jul. 2 at 1:29 AM
$VRNA my old family. $CAPR might have the same run as vrna by the end of the month, and end of next month!
3 · Reply
Jack_Danielss
Jack_Danielss Jun. 30 at 3:38 PM
$CYTK $VRNA vibes
0 · Reply
Kingjake26
Kingjake26 Jun. 30 at 2:21 PM
$CADL Totally agree. I believe $CADL is better than my $VRNA that was bought out at over $100 a share. Thats no pumping. That is just an opinion. Just do the homework
1 · Reply
Hawksssss
Hawksssss Jun. 20 at 5:20 AM
$VRNA revenue prior to and after buyout. Interesting dip in q1, not unlike many bios but quite sizable. Verona Ohtuvayre (ensifentrine) Revenue 3Q24: 5.6 mil; 4Q24: 35.65 mil; 1Q25: 76.3 mil 2Q25: 103.1 mil 3Q25: 136 mil 4Q25: 196 mil; 1Q26: 131 mil 2024: 41.2 mil 2025: 506 mil
1 · Reply
Hawksssss
Hawksssss Jun. 20 at 2:13 AM
$VRNA Apogee to be bought for 11 billion. Brief Clinical Outcome Comparison between Connect China phase 3 data and Apogee Efficacy (Week 16) 1. EASI-75: Rademikibart higher (74.2%) vs Zumilokibart (65.9%) 2. IGA 0/1 clearance: Nearly equal (Rademikibart 47.7% / Zumilokibart 46.0%) 3. EASI-90 deep clearance: Zumilokibart slightly better (47.4%) vs Rademikibart (43.0%) 4. Itch reduction: Rademikibart superior (54.7%) vs Zumilokibart (50.5%) Long-term 52-week maintenance • Rademikibart: Very high sustained response (EASI-75 96.6%, IGA 0/1 87.1%) with Q2W/Q4W dosing • Zumilokibart: 85% Week 16 responders kept EASI-75 with semi-annual ultra-long dosing Safety • Rademikibart: Lower conjunctivitis rate (3.9%) and mild overall adverse event rate • Zumilokibart: Higher conjunctivitis risk (10.6%–20.7% across doses); comparable general adverse event profile otherwise Onset speed • Rademikibart: Noticeable relief at Week 1 • Zumilokibart: Itch relief within 48 hours
0 · Reply
Hawksssss
Hawksssss Jun. 17 at 6:17 AM
$VRNA $XBI 3) The company said in March that the two acute readouts will be around mid year and will commence phase three for both acute and chronic athema. Remember Dupixent did 17.8 billion in sales. Company just raised 20 mil (it had 45 mil in cash) and insiders bought several million shares at 3.2 in the first half. It is now sitting at 2 or 125 million MC. The most important thing about this name is the fact that its China trial result was fantastic and US readouts are around the corner. So we are not really blind now. Eli Lilly and Perceptive have stake in the company. Do your own DD. Good luck!
0 · Reply
Hawksssss
Hawksssss Jun. 17 at 6:11 AM
$VRNA $VRNA $XBI if you are still around Verona. Came across this name $CNTB. It is also in the respiratory space. It has two phase 2 readouts within the next month for acute athema and COPD. There are not approved treatment for acute (emergency setting) athema or COPD. Verona’s drug is for chronic COPD, not acute. The company’s Chinese partner has finished phase 3 trial and filed a new drug application for eczema. 1)
0 · Reply
Hawksssss
Hawksssss Jun. 17 at 6:10 AM
$VRNA $CNTB 2) The Phase 3 trials in China have been a huge success. Rademikibart did not only meet its goals; it generated numbers that suggested that it could be better than the current market leader, Dupixent. In dermatology trials, eczema improvements are measured by the EASI score. By week 52, 96.6% of patients on rademikibart achieved EASI-75, which is huge compared to Dupixent, where only 65% of patients achieved EASI-75 at 52 weeks. EASI-90 was achieved by 85.3% of patients who achieved a 90% reduction in their eczema, an exceptionally high bar for a chronic autoimmune disease. For comparison, Dupixent achieved a score of 51% at 52 weeks.
0 · Reply
BioRich
BioRich Jun. 16 at 9:11 PM
$CRMD Quick look over at the gainers for today and I saw this grouping. How many Buyouts or deals did we have in this group? Good lord. Will $CRMD be added to that distinguished list? I think so. For fun, the 2 picks above the screen grab was $AKRO, one below was $NUVL. $TERN? $VRNA? Some real life changes in here. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
1 · Reply
BioRich
BioRich Jun. 15 at 3:37 PM
$MRK You bought $VRNA (thank you very much) so why not just work with Mr. Z to get a deal done for $SABS? That would be great appeciated as well. Cheers!
0 · Reply
BioRich
BioRich Jun. 15 at 3:35 PM
$SAB Thanks to @Trainguy1 for making this massive connection between $SABS's new/current Chairman of the Board (BoD) and $VRNA. Looks like Mr. Zaccardelli has a knack for productively progressing clinical drugs to approval, and then getting bought out. $SABS is one of the most under the radar, under valued stocks out there. I think we stumbled upon a winner. Thanks for the connection @Trainguy1 Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! $XBI
0 · Reply
JFais
JFais Jun. 14 at 2:07 PM
$VRNA - still can't believe I missed this one, but the W is applied learnings to $LQDA early launch metrics & bought in full-size. For each setback or missed opportunity, seek to turn the Loss into a Win by learning from it & apply going forward 👍
1 · Reply
rotehefe
rotehefe Jun. 8 at 8:34 PM
$CADL tik-tok tik-tok; another day passed by, free float gets reduced constantly and every day passes by we are one day closer to fantastic news. And then I would not like to be in the shoes of the short guys... keep strong hand with your shares, I see a big reward, remembers me to $VRNA
0 · Reply
De12
De12 May. 22 at 5:33 PM
$OLMA Druck had buyouts with $CDTX , $SWTX And $VRNA , Next is $OLMA Squeeeze!!
0 · Reply
stjernerogvann
stjernerogvann May. 19 at 2:32 PM
$SLS @yG19 is not wrong about these opportunities coming along so seldom. I got lucky that @Trainguy1 brought $VRNA to my attention - that was a no-brainer, too. But this one seems even more so... Getting this much insight into how a trial is going is rare. I hope that many retail people take advantage - at least in a small way.
1 · Reply
ShadowBull3745
ShadowBull3745 May. 15 at 6:48 PM
$CADL $CCXI $VRNA
0 · Reply
marked0ne
marked0ne May. 15 at 6:40 PM
$CADL i've been into a few awesome investor calls over the last few years ($VRNA , $CCXI) . But this is the best investors call i've heard. ever.
3 · Reply
Kingjake26
Kingjake26 May. 15 at 5:54 PM
$CADL Been part of several buyouts. I’m not sure what will happen here. Buyout or go on own but this is a multi billion dollar opportunity. I was part of big buyouts. $VRNA $MYOV CCXI. And a few others. Plus I own $CAPR with over 500% gain. Just a major opportunity My two two investments are CADL and CAPR
4 · Reply
marked0ne
marked0ne May. 15 at 5:35 PM
$CADL damn, i really thought my position was big enough. But damn, my belly tells me BUY BUY BUY! I get some serious $VRNA vibes here!
1 · Reply
TwongStocks
TwongStocks May. 12 at 11:44 AM
$VRNA Some former VRNA execs join ACHV https://www.globenewswire.com/news-release/2026/05/12/3292696/0/en/achieve-life-sciences-strengthens-board-and-commercial-leadership-with-three-senior-appointments-from-team-previously-at-verona-pharma.html Christopher Martin (former VRNA CCO) joined the Board of Directors. Mark Zappia joined as Senior Vice President, Commercial. He oversaw the commercial strategy for Ohtuvayre Jim Willis joined as Vice President of Sales and Sales Enablement. He led the Ohtuvayre national field force. “Bringing Chris, Mark, and Jim to Achieve is one of the most consequential decisions of my first month as CEO and reflects our evolution into a commercial-stage organization,” said Andrew D. Goldberg, MD, Chief Executive Officer of Achieve Life Sciences. “Having anchored Verona Pharma’s U.S. market transition, I saw firsthand the discipline and excellence this team brings to a commercial launch. We are addressing one of the largest preventable public health problems we know, and the experience this team brings positions Achieve to deliver cytisinicline to the patients who need it and the prescribers who care for them.”
0 · Reply
BigCh33z3
BigCh33z3 May. 10 at 12:26 PM
$VRNA I said BTFD ¯\_(ツ)_/¯
0 · Reply
BioStick123
BioStick123 May. 7 at 7:20 PM
$URGN $XBI $VRNA
0 · Reply